Ruth A Hackett1, Mika Kivimäki1, Meena Kumari1, Andrew Steptoe1. 1. Department of Epidemiology and Public Health (R.A.H., M.Ki., A.S.), University College London, London, WC1E 6BT, UK; Institute for Social and Economic Research (M.Ku.), University of Essex, Colchester, Essex, CO4 3SQ, UK.
Abstract
CONTEXT: The hypothalamic pituitary-adrenal axis is thought to play a role in type 2 diabetes (T2D). However, evidence for an association between cortisol and future glucose disturbance is sparse. OBJECTIVE: The aim was to examine the association of diurnal cortisol secretion with future T2D and impaired glucose metabolism in a community-dwelling population. DESIGN: This is a prospective cohort study of salivary cortisol measured at the 2002-2004 clinical examination of the Whitehall II study, United Kingdom. We measured cortisol (nmol/l) from six saliva samples obtained over the course of a day: at waking, +30 minutes, +2.5 hours, +8 hours, +12 hours, and bedtime. Participants who were normoglycemic in 2002-2004 (phase 7) were reexamined in 2012-2013 (phase 11). SETTING: The occupational cohort was originally recruited in 1985-1988. PARTICIPANTS: A total of 3270 men and women with an average age of 60.85 years at phase 7 (2002-2004). OUTCOME MEASURES: Incident T2D and impaired fasting glucose in 2012-2013 were measured. RESULTS: Raised evening cortisol at phase 7 was predictive of new-onset T2D at phase 11 (odds ratio [OR], 1.18; 95% confidence interval [CI], 1.01-1.37) with a trend for a flatter slope in participants with incident T2D (odds ratio, 1.15; 95% CI, 0.99-1.33). When expanding this analysis to a broader category of glucose disturbance we found that a flattened diurnal cortisol slope at phase 7 was predictive of future impaired fasting glucose or T2D at phase 11 (OR, 1.12; 95% CI, 1.02-1.22), as was high bedtime cortisol (OR, 1.10; 95% CI, 1.01-1.20). CONCLUSIONS: In this nonclinical population, alterations in diurnal cortisol patterns were predictive of future glucose disturbance.
CONTEXT: The hypothalamic pituitary-adrenal axis is thought to play a role in type 2 diabetes (T2D). However, evidence for an association between cortisol and future glucose disturbance is sparse. OBJECTIVE: The aim was to examine the association of diurnal cortisol secretion with future T2D and impaired glucose metabolism in a community-dwelling population. DESIGN: This is a prospective cohort study of salivary cortisol measured at the 2002-2004 clinical examination of the Whitehall II study, United Kingdom. We measured cortisol (nmol/l) from six saliva samples obtained over the course of a day: at waking, +30 minutes, +2.5 hours, +8 hours, +12 hours, and bedtime. Participants who were normoglycemic in 2002-2004 (phase 7) were reexamined in 2012-2013 (phase 11). SETTING: The occupational cohort was originally recruited in 1985-1988. PARTICIPANTS: A total of 3270 men and women with an average age of 60.85 years at phase 7 (2002-2004). OUTCOME MEASURES: Incident T2D and impaired fasting glucose in 2012-2013 were measured. RESULTS: Raised evening cortisol at phase 7 was predictive of new-onset T2D at phase 11 (odds ratio [OR], 1.18; 95% confidence interval [CI], 1.01-1.37) with a trend for a flatter slope in participants with incident T2D (odds ratio, 1.15; 95% CI, 0.99-1.33). When expanding this analysis to a broader category of glucose disturbance we found that a flattened diurnal cortisol slope at phase 7 was predictive of future impaired fasting glucose or T2D at phase 11 (OR, 1.12; 95% CI, 1.02-1.22), as was high bedtime cortisol (OR, 1.10; 95% CI, 1.01-1.20). CONCLUSIONS: In this nonclinical population, alterations in diurnal cortisol patterns were predictive of future glucose disturbance.
Authors: Orfeu M Buxton; Sean W Cain; Shawn P O'Connor; James H Porter; Jeanne F Duffy; Wei Wang; Charles A Czeisler; Steven A Shea Journal: Sci Transl Med Date: 2012-04-11 Impact factor: 17.956
Authors: F Lederbogen; J Hummel; C Fademrecht; B Krumm; C Kühner; M Deuschle; K-H Ladwig; C Meisinger; H-E Wichmann; H Lutz; B Breivogel Journal: Exp Clin Endocrinol Diabetes Date: 2011-04-06 Impact factor: 2.949
Authors: N Sarwar; P Gao; S R Kondapally Seshasai; R Gobin; S Kaptoge; E Di Angelantonio; E Ingelsson; D A Lawlor; E Selvin; M Stampfer; C D A Stehouwer; S Lewington; L Pennells; A Thompson; N Sattar; I R White; K K Ray; J Danesh Journal: Lancet Date: 2010-06-26 Impact factor: 202.731
Authors: J Hellhammer; E Fries; O W Schweisthal; W Schlotz; A A Stone; D Hagemann Journal: Psychoneuroendocrinology Date: 2006-11-28 Impact factor: 4.905
Authors: N Maneka G De Silva; Rachel M Freathy; Tom M Palmer; Louise A Donnelly; Jian'an Luan; Tom Gaunt; Claudia Langenberg; Michael N Weedon; Beverley Shields; Beatrice A Knight; Kirsten J Ward; Manjinder S Sandhu; Roger M Harbord; Mark I McCarthy; George Davey Smith; Shah Ebrahim; Andrew T Hattersley; Nicholas Wareham; Debbie A Lawlor; Andrew D Morris; Colin N A Palmer; Timothy M Frayling Journal: Diabetes Date: 2011-01-31 Impact factor: 9.461
Authors: Robin Ortiz; Bjoern Kluwe; James B Odei; Justin B Echouffo Tcheugui; Mario Sims; Rita R Kalyani; Alain G Bertoni; Sherita H Golden; Joshua J Joseph Journal: Psychoneuroendocrinology Date: 2018-12-27 Impact factor: 4.905
Authors: Jennifer R Piazza; Natalia O Dmitrieva; Susan T Charles; David M Almeida; Gabriel A Orona Journal: Health Psychol Date: 2018-07-19 Impact factor: 4.267
Authors: H Matthew Lehrer; Mary A Steinhardt; Susan K Dubois; Mark L Laudenslager Journal: Psychoneuroendocrinology Date: 2019-11-10 Impact factor: 4.905
Authors: Amit Tirosh; Maya B Lodish; Charalampos Lyssikatos; Elena Belyavskaya; Georgios Z Papadakis; Constantine A Stratakis Journal: Horm Res Paediatr Date: 2017-04-21 Impact factor: 2.852